AllianceBernstein’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-21,390
| Closed | -$112K | – | 3325 |
|
|
2024
Q1 | $112K | Hold |
21,390
| – | – | ﹤0.01% | 3016 |
|
|
2023
Q4 | $112K | Hold |
21,390
| – | – | ﹤0.01% | 3057 |
|
|
2023
Q3 | $337K | Sell |
21,390
-23,162
| -52% | -$416K | ﹤0.01% | 2758 |
|
|
2023
Q2 | $866K | Buy |
44,552
+2,555
| +6% | +$60.6K | ﹤0.01% | 2348 |
|
|
2023
Q1 | $1.19M | Sell |
41,997
-1,537
| -4% | -$45.6K | ﹤0.01% | 2136 |
|
|
2022
Q4 | $1.27M | Buy |
43,534
+3,978
| +10% | +$126K | ﹤0.01% | 2163 |
|
|
2022
Q3 | $1.04M | Sell |
39,556
-304
| -0.8% | -$11.2K | ﹤0.01% | 2264 |
|
|
2022
Q2 | $1.77M | Sell |
39,860
-89
| -0.2% | -$4.09K | ﹤0.01% | 2021 |
|
|
2022
Q1 | $1.98M | Sell |
39,949
-784
| -2% | -$37.6K | ﹤0.01% | 2095 |
|
|
2021
Q4 | $2.07M | Buy |
40,733
+11
| +0% | +$570 | ﹤0.01% | 2125 |
|
|
2021
Q3 | $2.27M | Sell |
40,722
-1,557
| -4% | -$76.6K | ﹤0.01% | 2090 |
|
|
2021
Q2 | $1.81M | Buy |
42,279
+7,157
| +20% | +$295K | ﹤0.01% | 2254 |
|
|
2021
Q1 | $1.47M | Buy |
35,122
+6,590
| +23% | +$306K | ﹤0.01% | 2248 |
|
|
2020
Q4 | $1.33M | Sell |
28,532
-1,700
| -6% | -$79.5K | ﹤0.01% | 2183 |
|
|
2020
Q3 | $1.28M | Sell |
30,232
-4,758
| -14% | -$208K | ﹤0.01% | 2073 |
|
|
2020
Q2 | $1.68M | Sell |
34,990
-50
| -0.1% | -$2.5K | ﹤0.01% | 1941 |
|
|
2020
Q1 | $1.61M | Sell |
35,040
-600
| -2% | -$30.1K | ﹤0.01% | 1794 |
|
|
2019
Q4 | $2.14M | Buy |
35,640
+100
| +0.3% | +$5.96K | ﹤0.01% | 1922 |
|
|
2019
Q3 | $2.01M | Sell |
35,540
-2,400
| -6% | -$135K | ﹤0.01% | 1908 |
|
|
2019
Q2 | $2.11M | Buy |
37,940
+880
| +2% | +$45.9K | ﹤0.01% | 1945 |
|
|
2019
Q1 | $1.87M | Sell |
37,060
-4,100
| -10% | -$182K | ﹤0.01% | 1932 |
|
|
2018
Q4 | $1.66M | Sell |
41,160
-2,660
| -6% | -$137K | ﹤0.01% | 1937 |
|
|
2018
Q3 | $3.04M | Buy |
43,820
+20
| +0% | +$1.52K | ﹤0.01% | 1642 |
|
|
2018
Q2 | $3.31M | Buy |
43,800
+25,682
| +142% | +$1.62M | ﹤0.01% | 1545 |
|
|
2018
Q1 | $955K | Sell |
18,118
-13,992
| -44% | -$814K | ﹤0.01% | 2280 |
|
|
2017
Q4 | $1.72M | Buy |
32,110
+3,600
| +13% | +$200K | ﹤0.01% | 1956 |
|
|
2017
Q3 | $1.7M | Sell |
28,510
-1,260
| -4% | -$76.2K | ﹤0.01% | 1957 |
|
|
2017
Q2 | $2.35M | Buy |
29,770
+15,270
| +105% | +$1.25M | ﹤0.01% | 1723 |
|
|
2017
Q1 | $1.2M | Sell |
14,500
-1,100
| -7% | -$81.8K | ﹤0.01% | 2150 |
|
|
2016
Q4 | $1.24M | Hold |
15,600
| – | – | ﹤0.01% | 2162 |
|
|
2016
Q3 | $1.09M | Hold |
15,600
| – | – | ﹤0.01% | 2183 |
|
|
2016
Q2 | $605K | Hold |
15,600
| – | – | ﹤0.01% | 2442 |
|
|
2016
Q1 | $632K | Buy |
15,600
+300
| +2% | +$19K | ﹤0.01% | 2326 |
|
|
2015
Q4 | $1.36M | Sell |
15,300
-370
| -2% | -$29.2K | ﹤0.01% | 1928 |
|
|
2015
Q3 | $1.16M | Sell |
15,670
-30
| -0.2% | -$2.5K | ﹤0.01% | 2068 |
|
|
2015
Q2 | $1.27M | Buy |
+15,700
| New | +$1.02M | ﹤0.01% | 2137 |
|
Other funds holding EGRX
NCM
ACM
AllianceBernstein's EGRX Position: Q2 2024 in Review
AllianceBernstein sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 21,390 shares — an estimated $112K sold.
AllianceBernstein first reported a position in EGRX in Q2 2015 and held it in 36 quarters. The position peaked at $3.31M in Q2 2018. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.
- AllianceBernstein reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
- AllianceBernstein sold 21,390 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $112K.
- AllianceBernstein first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 36 quarters.
- AllianceBernstein's Eagle Pharmaceuticals, Inc. position peaked at $3.31M in Q2 2018.
- 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.
Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.